These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

313 related articles for article (PubMed ID: 9707425)

  • 1. Retention of wild-type p53 in tumors from p53 heterozygous mice: reduction of p53 dosage can promote cancer formation.
    Venkatachalam S; Shi YP; Jones SN; Vogel H; Bradley A; Pinkel D; Donehower LA
    EMBO J; 1998 Aug; 17(16):4657-67. PubMed ID: 9707425
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Is p53 haploinsufficient for tumor suppression? Implications for the p53+/- mouse model in carcinogenicity testing.
    Venkatachalam S; Tyner SD; Pickering CR; Boley S; Recio L; French JE; Donehower LA
    Toxicol Pathol; 2001; 29 Suppl():147-54. PubMed ID: 11695551
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of spontaneous mammary tumors in BALB/c p53 heterozygous mice. A model for Li-Fraumeni syndrome.
    Kuperwasser C; Hurlbut GD; Kittrell FS; Dickinson ES; Laucirica R; Medina D; Naber SP; Jerry DJ
    Am J Pathol; 2000 Dec; 157(6):2151-9. PubMed ID: 11106587
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Atm heterozygosity does not increase tumor susceptibility to ionizing radiation alone or in a p53 heterozygous background.
    Mao JH; Wu D; DelRosario R; Castellanos A; Balmain A; Perez-Losada J
    Oncogene; 2008 Nov; 27(51):6596-600. PubMed ID: 18679420
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increased tumor cell proliferation in murine tumors with decreasing dosage of wild-type p53.
    Tyner SD; Choi J; Laucirica R; Ford RJ; Donehower LA
    Mol Carcinog; 1999 Mar; 24(3):197-208. PubMed ID: 10204804
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumor spectrum analysis in p53-mutant mice.
    Jacks T; Remington L; Williams BO; Schmitt EM; Halachmi S; Bronson RT; Weinberg RA
    Curr Biol; 1994 Jan; 4(1):1-7. PubMed ID: 7922305
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Loss of heterozygosity frequency at the Trp53 locus in p53-deficient (+/-) mouse tumors is carcinogen-and tissue-dependent.
    French JE; Lacks GD; Trempus C; Dunnick JK; Foley J; Mahler J; Tice RR; Tennant RW
    Carcinogenesis; 2001 Jan; 22(1):99-106. PubMed ID: 11159747
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immune deficiency augments the prevalence of p53 loss of heterozygosity in spontaneous tumors but not bi-directional loss of heterozygosity in bone marrow progenitors.
    Shetzer Y; Napchan Y; Kaufman T; Molchadsky A; Tal P; Goldfinger N; Rotter V
    Int J Cancer; 2017 Mar; 140(6):1364-1369. PubMed ID: 28008605
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours.
    Donehower LA; Harvey M; Slagle BL; McArthur MJ; Montgomery CA; Butel JS; Bradley A
    Nature; 1992 Mar; 356(6366):215-21. PubMed ID: 1552940
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chromosome 11 allelotypes reflect a mechanism of chemical carcinogenesis in heterozygous p53-deficient mice.
    Hulla JE; French JE; Dunnick JK
    Carcinogenesis; 2001 Jan; 22(1):89-98. PubMed ID: 11159746
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phenolphthalein induces thymic lymphomas accompanied by loss of the p53 wild type allele in heterozygous p53-deficient (+/-) mice.
    Dunnick JK; Hardisty JF; Herbert RA; Seely JC; Furedi-Machacek EM; Foley JF; Lacks GD; Stasiewicz S; French JE
    Toxicol Pathol; 1997; 25(6):533-40. PubMed ID: 9437796
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of genetic background on tumorigenesis in p53-deficient mice.
    Donehower LA; Harvey M; Vogel H; McArthur MJ; Montgomery CA; Park SH; Thompson T; Ford RJ; Bradley A
    Mol Carcinog; 1995 Sep; 14(1):16-22. PubMed ID: 7546219
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumor susceptibility of p21(Waf1/Cip1)-deficient mice.
    Martín-Caballero J; Flores JM; García-Palencia P; Serrano M
    Cancer Res; 2001 Aug; 61(16):6234-8. PubMed ID: 11507077
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Loss of heterozygosity occurs via mitotic recombination in Trp53+/- mice and associates with mammary tumor susceptibility of the BALB/c strain.
    Blackburn AC; McLary SC; Naeem R; Luszcz J; Stockton DW; Donehower LA; Mohammed M; Mailhes JB; Soferr T; Naber SP; Otis CN; Jerry DJ
    Cancer Res; 2004 Aug; 64(15):5140-7. PubMed ID: 15289317
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A mutant p53 transgene accelerates tumour development in heterozygous but not nullizygous p53-deficient mice.
    Harvey M; Vogel H; Morris D; Bradley A; Bernstein A; Donehower LA
    Nat Genet; 1995 Mar; 9(3):305-11. PubMed ID: 7773294
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Disruption of the ARF transcriptional activator DMP1 facilitates cell immortalization, Ras transformation, and tumorigenesis.
    Inoue K; Wen R; Rehg JE; Adachi M; Cleveland JL; Roussel MF; Sherr CJ
    Genes Dev; 2000 Jul; 14(14):1797-809. PubMed ID: 10898794
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Detection of both mutant and wild-type p53 protein in normal skin fibroblasts and demonstration of a shared 'second hit' on p53 in diverse tumors from a cancer-prone family with Li-Fraumeni syndrome.
    Srivastava S; Tong YA; Devadas K; Zou ZQ; Sykes VW; Chen Y; Blattner WA; Pirollo K; Chang EH
    Oncogene; 1992 May; 7(5):987-91. PubMed ID: 1373881
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nbn heterozygosity renders mice susceptible to tumor formation and ionizing radiation-induced tumorigenesis.
    Dumon-Jones V; Frappart PO; Tong WM; Sajithlal G; Hulla W; Schmid G; Herceg Z; Digweed M; Wang ZQ
    Cancer Res; 2003 Nov; 63(21):7263-9. PubMed ID: 14612522
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Selection for loss of p53 function in T-cell lymphomagenesis is alleviated by Moloney murine leukemia virus infection in myc transgenic mice.
    Baxter EW; Blyth K; Cameron ER; Neil JC
    J Virol; 2001 Oct; 75(20):9790-8. PubMed ID: 11559812
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification and characterization of potential human carcinogens using B6.129tm1Trp53 heterozygous null mice and loss of heterozygosity at the Trp53 locus.
    French JE
    IARC Sci Publ; 2004; (157):271-87. PubMed ID: 15055301
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.